+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study



A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study



International Journal of Cancer 128(10): 2415-2424



Immunochemical fecal occult blood test (FIT) is a new colorectal cancer (CRC) screening method already recommended by the American screening guidelines. We aimed to test the feasibility of FIT as compared to guaiac fecal occult blood test (G-FOBT) in a large urban population of Tel Aviv. Average-risk persons, aged 50-75 years, were offered FIT or G-FOBT after randomization according to the socioeconomic status of their clinics. Participants with positive tests underwent colonoscopy. Participants were followed through the Cancer Registry 2 years after the study. Hemoccult SENSA™ and OC-MICRO™ (three samples, 70 ng/ml threshold) were used. FIT was offered to 4,657 persons (Group A) and G-FOBT to 7,880 persons (Group B). Participation rate was 25.9% and 28.8% in Group A and B, respectively (p < 0.001). Positivity rate in Group A and B was 12.7% and 3.9%, respectively (p < 0.001). Cancer found in six (0.49%) and eight (0.35%) patients of Group A and B, respectively (NS). Cancer registry follow-up found missed cancer in five (0.22%) cases of Group B and none in Group A (NS). The sensitivity, specificity, negative and positive predictive value for cancer in Group A and B were 100%, 85.9%, 100%, 3.9% and 61.5%, 96.4%, 99.8%, 9.1%, respectively. There was increased detection of advanced adenomatous polyp (AAP) by FIT, irrespective of age, gender, and socioeconomic status (Per Protocol: odds ratio 2.69, 95% confidence interval 1.6-4.5; Intention to Screen: odds ratio 3.16, 95% confidence interval 1.8-5.4). FIT is feasible in urban, average-risk population, which significantly improved performance for detection of AAP and CRC, despite reduced participation.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 051145417

Download citation: RISBibTeXText

PMID: 20658527

DOI: 10.1002/ijc.25574


Related references

Detection rate of immunochemical fecal occult blood test for colorectal adenomatous polyps with severe dysplasia. Journal Of Gastroenterology. 32(4): 492-495, 1997

Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 107(9): 2152-2159, 2006

Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer 109(9): 1925-6; Author Reply 1926, 2007

Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Preventive Medicine 50(5-6): 297-299, 2010

T2023 Randomized Trial Comparing the Test Characteristics of Immunochemical Fecal Occult Blood Test At Different Cut-Off Levels to Guaiac-Based Fecal Occult Blood Test. Gastroenterology 136(5): A-622, 2009

Immunochemical detection of fecal occult blood--the fecal smear punch-disc test: a new non-invasive screening test for colorectal cancer. Cancer 45(5 Suppl.): 1099-1102, 1980

Immunochemical detection of fecal occult blood . The fecal smear punch-disc test: A new non-invasive screening test for colorectal cancer. Cancer 45(S5): 1099-1102, 1980

Screening test for colorectal cancer. Practical experiences with fecal testing for occult blood. 2: Rate of a false-negative occult blood test. Zeitschrift für Arztliche Fortbildung 81(20): 1057-1059, 1987

The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. Journal of Medical Screening 12(2): 83-88, 2005

Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. Journal of Digestive Diseases 11(3): 148-160, 2010

Cost-effectiveness of colorectal cancer screening with an immunochemical fecal occult blood test versus guaiac FOBT. American Journal of Gastroenterology 98(9 Suppl.): S221-S222, 2003

Tu1904 Interval Cancer After Patients Undergoing Immunochemical Fecal Occult Blood (Fit) or Guaiac Fecal Occult Test (gFobt) in a Population Based Study: Fit Is Protective for up to 3 Years. Gastroenterology 144(5): S-877, 2013

Comparison of a New-generation Fecal Immunochemical Test (FIT) With Guaiac Fecal Occult Blood Test (gFOBT) in Detecting Colorectal Neoplasia Among Colonoscopy-referral Patients. Anticancer Research 39(1): 261-269, 2018

Screen compliance rates in 14-years annual screening program for colorectal cancer with immunochemical fecal occult blood test-- identification of higher priority subjects in health education. European Journal of Medical Research 3(7): 341-344, 1998

Age-related cancer detection rate and costs for one cancer detected in one screening by immunochemical fecal occult blood test. Diseases of the Colon and Rectum 44(11): 1696-1699, 2001